CN102858803A - 中和催乳素受体抗体及其治疗用途 - Google Patents

中和催乳素受体抗体及其治疗用途 Download PDF

Info

Publication number
CN102858803A
CN102858803A CN2010800634488A CN201080063448A CN102858803A CN 102858803 A CN102858803 A CN 102858803A CN 2010800634488 A CN2010800634488 A CN 2010800634488A CN 201080063448 A CN201080063448 A CN 201080063448A CN 102858803 A CN102858803 A CN 102858803A
Authority
CN
China
Prior art keywords
seq
antibody
antibodies
prlr
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800634488A
Other languages
English (en)
Chinese (zh)
Inventor
C·奥托
S·沃尔夫
C·弗莱贝格
A·哈尔恩加
S·格雷文
M·特劳特魏茵
S·布鲁德
A·艾克
A·威尔恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Intellectual Property GmbH
Original Assignee
Bayer Intellectual Property GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102858803(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Intellectual Property GmbH filed Critical Bayer Intellectual Property GmbH
Publication of CN102858803A publication Critical patent/CN102858803A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN2010800634488A 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途 Pending CN102858803A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09075546.3 2009-12-10
EP09075546A EP2332995A1 (en) 2009-12-10 2009-12-10 Neutralizing prolactin receptor antibodies and their therapeutic use
PCT/EP2010/067740 WO2011069794A1 (en) 2009-12-10 2010-11-18 Neutralizing prolactin receptor antibodies and their therapeutic use

Publications (1)

Publication Number Publication Date
CN102858803A true CN102858803A (zh) 2013-01-02

Family

ID=42091520

Family Applications (6)

Application Number Title Priority Date Filing Date
CN201080063268XA Pending CN102858801A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN201080063347.0A Active CN102947338B (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN2010800633485A Pending CN102741291A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN2010800634492A Pending CN102858804A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN201080063269.4A Active CN102884082B (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN2010800634488A Pending CN102858803A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途

Family Applications Before (5)

Application Number Title Priority Date Filing Date
CN201080063268XA Pending CN102858801A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN201080063347.0A Active CN102947338B (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN2010800633485A Pending CN102741291A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN2010800634492A Pending CN102858804A (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途
CN201080063269.4A Active CN102884082B (zh) 2009-12-10 2010-11-18 中和催乳素受体抗体及其治疗用途

Country Status (40)

Country Link
US (6) US20130171147A1 (enExample)
EP (13) EP2332995A1 (enExample)
JP (7) JP2013513363A (enExample)
KR (2) KR101790366B1 (enExample)
CN (6) CN102858801A (enExample)
AP (1) AP2012006343A0 (enExample)
AR (6) AR079349A1 (enExample)
AU (2) AU2010330165B2 (enExample)
BR (2) BR112012014048B1 (enExample)
CA (6) CA2783513C (enExample)
CL (2) CL2012001540A1 (enExample)
CR (2) CR20120312A (enExample)
CU (2) CU23973B1 (enExample)
CY (2) CY1118209T1 (enExample)
DK (2) DK2510002T3 (enExample)
DO (2) DOP2012000159A (enExample)
EA (2) EA029327B1 (enExample)
EC (2) ECSP12011965A (enExample)
ES (2) ES2610654T3 (enExample)
GT (1) GT201200186A (enExample)
HR (2) HRP20170016T1 (enExample)
HU (2) HUE031631T2 (enExample)
IL (2) IL220149A (enExample)
IN (2) IN2012DN05078A (enExample)
LT (2) LT2510002T (enExample)
MA (1) MA33888B1 (enExample)
ME (1) ME02577B (enExample)
MX (2) MX339343B (enExample)
NZ (2) NZ600511A (enExample)
PE (3) PE20121360A1 (enExample)
PH (2) PH12012501131A1 (enExample)
PL (2) PL2510002T3 (enExample)
PT (2) PT2510006T (enExample)
RS (2) RS55589B1 (enExample)
SG (2) SG181511A1 (enExample)
SI (2) SI2510006T1 (enExample)
TN (1) TN2012000294A1 (enExample)
TW (5) TWI487536B (enExample)
WO (6) WO2011069797A1 (enExample)
ZA (2) ZA201204213B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
DK3345615T3 (da) 2010-03-01 2020-01-20 Bayer Healthcare Llc Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi)
EP2530089A1 (en) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Neutralising prolactin receptor antibody Mat3 and its therapeutical use
EA036225B1 (ru) 2012-03-14 2020-10-15 Ридженерон Фармасьютикалз, Инк. Мультиспецифические антигенсвязывающие молекулы и их применения
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
DK2935331T3 (en) 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
CN105025925A (zh) * 2013-03-15 2015-11-04 拜尔健康护理有限责任公司 抗-催乳素受体抗体制剂
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
WO2015168474A1 (en) 2014-04-30 2015-11-05 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
KR20170105558A (ko) 2015-01-30 2017-09-19 각코우호우징 사이타마이카다이가쿠 항 alk2 항체
JP6993958B2 (ja) 2015-07-06 2022-02-04 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 多重特異性抗原結合分子およびその使用
EP3448891A1 (en) 2016-04-28 2019-03-06 Regeneron Pharmaceuticals, Inc. Methods of making multispecific antigen-binding molecules
MX2019006131A (es) 2016-11-29 2019-08-21 Regeneron Pharma Metodos para tratar cancer de mama positivo para prlr.
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
JP2020519639A (ja) * 2017-05-12 2020-07-02 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． トリアザスピロ［４．５］デカノンによる胃不全麻痺の処置
US20210128728A1 (en) 2017-07-10 2021-05-06 Bayer Pharma Aktiengesellschaft Prolactin receptor antibody for male and female pattern hair loss
AU2019218892B2 (en) 2018-02-07 2025-08-14 Regeneron Pharmaceuticals, Inc. Methods and compositions for therapeutic protein delivery
WO2019169330A1 (en) * 2018-03-02 2019-09-06 Oncolix, Inc. Method for treating cancers expressing prolactin receptor
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
AR124681A1 (es) 2021-01-20 2023-04-26 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN118834297A (zh) * 2023-04-24 2024-10-25 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269438A1 (en) * 2005-10-05 2007-11-22 Brian Elenbaas Antibodies to the Human Prolactin Receptor
WO2008022295A2 (en) * 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2001500865A (ja) * 1996-09-13 2001-01-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ 避妊の非ホルモン法
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (en) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mammal prolactin variants
AU2003300904A1 (en) * 2002-12-13 2004-07-09 The Ohio State University Antagonists for human prolactin
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
ATE541585T1 (de) * 2004-10-28 2012-02-15 Kyowa Hakko Kirin Co Ltd Antikörper gegen il-5-rezeptor zur verwendung in der behandlung von endometriose.
WO2006089678A2 (en) * 2005-02-22 2006-08-31 Bioinvent International Ab Antibodies and peptides binding to hiv tat, and uses thereof
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
CN102711773A (zh) 2007-05-30 2012-10-03 奥克兰联合服务有限公司 生长激素和相关激素的抑制剂,和其使用方法
EP2332995A1 (en) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralizing prolactin receptor antibodies and their therapeutic use
WO2011139375A1 (en) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Antibodies directed against carbonic anhydrase ix and methods and uses thereof
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070269438A1 (en) * 2005-10-05 2007-11-22 Brian Elenbaas Antibodies to the Human Prolactin Receptor
WO2008022295A2 (en) * 2006-08-18 2008-02-21 Novartis Ag Prlr-specific antibody and uses thereof
EP2025683A1 (en) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variants of prolactin as antagonists of its receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
H.G. BOHNET，ET AL.: "n vivo effects of antisera to prolactin receptors in female rats", 《ENDOCRINOLOGY SOCIETY》 *
JANICE F. SISSOM,ET AL.: "Anti-Growth Action on Mouse Mammary and Prostate Glands ofa Monoclonal Antibody to Prolactin Receptor", 《AMERICAN JOURNAL OFPATHOLOGY》 *
LUISA BERMEJO MARTINEZ，ET AL.: "Prolactin receptor in human endometriotic tissues", 《ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA》 *

Also Published As

Publication number Publication date
IN2012DN05082A (enExample) 2015-10-09
BR112012015852A2 (pt) 2017-05-23
WO2011069797A1 (en) 2011-06-16
PE20121561A1 (es) 2012-11-25
GT201200186A (es) 2014-01-06
TWI487536B (zh) 2015-06-11
US20130272968A1 (en) 2013-10-17
AU2010330165A1 (en) 2012-07-19
DOP2012000159A (es) 2012-09-30
CA2783654A1 (en) 2011-06-16
WO2011069795A1 (en) 2011-06-16
DK2510002T3 (en) 2016-11-28
EP2567978A1 (en) 2013-03-13
MX2012006621A (es) 2012-10-05
ES2603352T3 (es) 2017-02-27
CU20120093A7 (es) 2012-10-15
WO2011069799A1 (en) 2011-06-16
EP2510002B1 (en) 2016-08-24
TW201138817A (en) 2011-11-16
SG181513A1 (en) 2012-07-30
NZ600512A (en) 2014-11-28
PT2510002T (pt) 2016-11-23
AR079352A1 (es) 2012-01-18
AU2010330161A1 (en) 2012-07-05
CN102884082B (zh) 2015-05-20
WO2011069795A4 (en) 2011-08-18
KR101790366B1 (ko) 2017-10-26
RS55277B1 (sr) 2017-02-28
IL220149A0 (en) 2012-07-31
HK1180354A1 (en) 2013-10-18
US20130171147A1 (en) 2013-07-04
EA029327B1 (ru) 2018-03-30
EA028678B1 (ru) 2017-12-29
LT2510002T (lt) 2016-11-25
ME02577B (me) 2017-06-20
IL220151A0 (en) 2012-07-31
PL2510002T3 (pl) 2017-02-28
JP6199930B2 (ja) 2017-09-20
AR079351A1 (es) 2012-01-18
TW201130505A (en) 2011-09-16
CL2012001539A1 (es) 2012-10-12
SI2510006T1 (sl) 2017-02-28
LT2510006T (lt) 2016-12-12
WO2011069798A1 (en) 2011-06-16
EP2567979A1 (en) 2013-03-13
CR20120312A (es) 2012-08-27
CA2783678A1 (en) 2011-06-16
ZA201204214B (en) 2014-08-27
SI2510002T1 (sl) 2016-12-30
US9241989B2 (en) 2016-01-26
HRP20170016T1 (hr) 2017-02-24
AR079348A1 (es) 2012-01-18
JP2013513365A (ja) 2013-04-22
EP2570436A1 (en) 2013-03-20
EP2510002A1 (en) 2012-10-17
KR20120112528A (ko) 2012-10-11
EP2510004A1 (en) 2012-10-17
AR079349A1 (es) 2012-01-18
EP2332995A1 (en) 2011-06-15
EP2510006B1 (en) 2016-11-09
CN102858804A (zh) 2013-01-02
EA201200851A1 (ru) 2013-01-30
EP2567980A1 (en) 2013-03-13
CA2783513C (en) 2018-08-14
PE20121360A1 (es) 2012-10-11
EP2510007A1 (en) 2012-10-17
IL220149A (en) 2017-09-28
US20130129739A1 (en) 2013-05-23
CN102884082A (zh) 2013-01-16
EP2510005A1 (en) 2012-10-17
US20120321632A1 (en) 2012-12-20
CY1118407T1 (el) 2017-06-28
IN2012DN05078A (enExample) 2015-10-23
JP2013513559A (ja) 2013-04-22
JP6066474B2 (ja) 2017-01-25
BR112012014048B1 (pt) 2021-10-26
BR112012015852B1 (pt) 2020-12-29
CN102947338B (zh) 2015-11-25
CU23973B1 (es) 2013-12-27
CL2012001540A1 (es) 2013-01-18
PH12012501131A1 (en) 2017-08-23
MX339343B (es) 2016-05-20
TN2012000294A1 (en) 2013-12-12
TW201130506A (en) 2011-09-16
CN102741291A (zh) 2012-10-17
CA2783513A1 (en) 2011-06-16
MA33888B1 (fr) 2013-01-02
ZA201204213B (en) 2014-08-27
CN102947338A (zh) 2013-02-27
ECSP12011966A (es) 2012-07-31
US20120315276A1 (en) 2012-12-13
HK1180700A1 (en) 2013-10-25
HRP20161401T1 (hr) 2016-12-16
AU2010330165B2 (en) 2015-07-16
NZ600511A (en) 2014-01-31
CA2783610A1 (en) 2011-06-16
MX2012006620A (es) 2012-06-21
TWI508744B (zh) 2015-11-21
PL2510006T3 (pl) 2017-06-30
AR079641A1 (es) 2012-02-08
DK2510006T3 (en) 2017-01-23
JP2013513363A (ja) 2013-04-22
CN102858801A (zh) 2013-01-02
BR112012014048A2 (pt) 2017-10-31
DOP2012000160A (es) 2012-09-30
SG181511A1 (en) 2012-07-30
CU20120092A7 (es) 2012-10-15
WO2011069794A1 (en) 2011-06-16
TW201130507A (en) 2011-09-16
JP2013513362A (ja) 2013-04-22
BR112012015852A8 (pt) 2017-06-27
ECSP12011965A (es) 2012-07-31
CA2783610C (en) 2018-10-30
JP2013513364A (ja) 2013-04-22
AR079350A1 (es) 2012-01-18
EP2570435A1 (en) 2013-03-20
WO2011069796A1 (en) 2011-06-16
EP2510006A1 (en) 2012-10-17
EP2567977A1 (en) 2013-03-13
JP2015180690A (ja) 2015-10-15
ES2610654T3 (es) 2017-04-28
AP2012006343A0 (en) 2012-06-30
CA2783514A1 (en) 2011-06-16
BR112012015852B8 (pt) 2021-05-25
RS55589B1 (sr) 2017-06-30
PT2510006T (pt) 2017-01-20
US9649374B2 (en) 2017-05-16
PE20171134A1 (es) 2017-08-09
KR20120112527A (ko) 2012-10-11
CR20120310A (es) 2012-08-01
JP2013513361A (ja) 2013-04-22
TW201130504A (en) 2011-09-16
PH12012501129A1 (en) 2012-11-05
CA2783651A1 (en) 2011-06-16
KR101765968B1 (ko) 2017-08-08
HUE031631T2 (en) 2017-07-28
AU2010330161B2 (en) 2015-07-09
HUE030143T2 (en) 2017-04-28
CY1118209T1 (el) 2017-06-28
EP2510003A1 (en) 2012-10-17
EA201200860A1 (ru) 2013-01-30
US20130022606A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
CN102884082B (zh) 中和催乳素受体抗体及其治疗用途
HK1180352A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
HK1180700B (en) Neutralizing prolactin receptor antibodies and their therapeutic use
HK1180353A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
HK1172632A (en) Neutralizing prolactin receptor antibodies and their therapeutic use
HK1180351A (en) Neutralizing prolactin receptor antibodies and their therapeutic use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1180352

Country of ref document: HK

AD01 Patent right deemed abandoned

Effective date of abandoning: 20130102

C20 Patent right or utility model deemed to be abandoned or is abandoned